Epilepsy Market in the US 2015-2019
|発行||TechNavio (Infiniti Research Ltd.)||商品コード||322803|
|出版日||ページ情報||英文 64 Pages
|米国のてんかん市場 Epilepsy Market in the US 2015-2019|
|出版日: 2015年01月07日||ページ情報: 英文 64 Pages||
Epilepsy is a spectrum of brain disorders varying from benign to severe, disabling, and life-threatening symptoms. It is caused by various factors ranging from brain malformations and tumors to meningitis, high-risk pregnancies, and birth trauma. However, when the underlying cause of the disease is unidentified, as in the majority of the cases, it is known as idiopathic epilepsy. Epilepsy is characterized by repeated occurrence of generalized or focal seizures. An imbalance between the inhibitory and excitatory signals of the brain, leading to a sudden onset of excitation, results in seizures. Occurrence of two or more unprovoked seizures is an important criterion to diagnose a person as being epileptic.
TechNavio's analysts forecast the Epilepsy market in the US to grow at a CAGR of 4.85 percent over the period 2014-2019.
The Epilepsy market in the US can be divided into three segments: First-generation Drugs, Second-generation Drugs, and Third-generation Drugs. This report covers the present scenario and the growth prospects of the Epilepsy market in the US for the period 2015-2019. To calculate the market size, the report considers the revenue generated through the sales of anti-epileptic drugs approved in the US to treat the symptoms of epilepsy.
TechNavio's report, Epilepsy Market in the US 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the landscape of the Epilepsy Market in the US and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.